Answers are grounded in this paper and cite their sources.
Review explores how oral β-lactams can be effectively utilized for systemic gram-negative infections, suggesting nuanced decision-making based on pharmacokinetics.
Oral β-lactams are frequently referred to as low bioavailability agents that are inferior in the treatment of systemic gram-negative infections. This notion limits their utility beyond their use. The pharmacokinetic/pharmacodynamic profiles of oral β-lactams differ among agents, and each agent must be considered individually in the context of the patient. In this review, we describe 3 scenarios where oral β-lactams may play a role in the treatment of systemic gram-negative infections and the decision process to select or avoid these agents. Each case represents a risk-vs-benefit scenario in which the degree of confidence in using an oral β-lactam varies.
No takes yet. Share an insight, caveat, or question.
Shif et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: